用于优化和个性化治疗儿童炎症性肠病中抗 TNF 药物的生物标志物
Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease.
作者信息
Salvador-Martín Sara, Melgarejo-Ortuño Alejandra, López-Fernández Luis A
机构信息
Servicio de Farmacia, Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain.
Spanish Clinical Research Network (SCReN), 28040 Madrid, Spain.
出版信息
Pharmaceutics. 2021 Oct 26;13(11):1786. doi: 10.3390/pharmaceutics13111786.
Abstract
The use of biological drugs has improved outcomes in pediatric inflammatory bowel disease (IBD). Prediction of the response to biological drugs would be extremely useful in IBD, and even more so in children, who are still growing physically and psychologically. Specific clinical, biochemical, and genetic parameters are considered predictive of response to biological drugs, although few studies have been carried out in children with IBD. In this review, we present current evidence on biological treatments used in pediatric IBD and the available biomarkers of response. We examine demographics, clinical characteristics, biomarkers (genetic, genomic, and cellular), and microbiota.
摘要
生物药物的使用改善了儿童炎症性肠病（IBD）的治疗效果。预测对生物药物的反应在IBD中非常有用，对于仍在身心发育阶段的儿童来说更是如此。尽管针对IBD儿童的研究较少，但特定的临床、生化和基因参数被认为可预测对生物药物的反应。在本综述中，我们介绍了目前关于儿童IBD生物治疗及可用反应生物标志物的证据。我们研究了人口统计学、临床特征、生物标志物（基因、基因组和细胞）以及微生物群。
相似文献
1
Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease.用于优化和个性化治疗儿童炎症性肠病中抗 TNF 药物的生物标志物
Pharmaceutics. 2021 Oct 26;13(11):1786. doi: 10.3390/pharmaceutics13111786.
2
Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children.作为炎症性肠病风险或抗 TNF 药物抗原性的多态性标志物，在儿童中的反应。
Pharmacol Res. 2023 Aug;194:106859. doi: 10.1016/j.phrs.2023.106859. Epub 2023 Jul 19.
3
Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.英夫利昔单抗和其他抗肿瘤坏死因子 α 治疗药物治疗炎症性肠病。
BioDrugs. 2010 Dec 14;24 Suppl 1:3-14. doi: 10.2165/11586290-000000000-00000.
4
Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.与溃疡性结肠炎相关的泛发性坏疽性脓皮病：英夫利昔单抗和硫唑嘌呤治疗成功
Acta Dermatovenerol Croat. 2016 Apr;24(1):83-5.
6
Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.炎症性肠病患者对生物治疗（抗 TNF、Vedolizumab 和 Ustekinumab）的主要反应的预测因素：从基础科学到临床实践。
J Crohns Colitis. 2020 Jun 19;14(5):694-709. doi: 10.1093/ecco-jcc/jjz195.
7
Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review.抗肿瘤坏死因子治疗小儿炎症性肠病的严重感染或淋巴瘤风险：系统评价。
Clin Gastroenterol Hepatol. 2014 Sep;12(9):1443-51; quiz e88-9. doi: 10.1016/j.cgh.2014.01.021. Epub 2014 Jan 22.
8
A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease.抗 TNF 在儿童和青少年炎症性肠病中的应用综述
Int J Mol Sci. 2019 May 23;20(10):2529. doi: 10.3390/ijms20102529.
9
Gut Microbiota Offers Universal Biomarkers across Ethnicity in Inflammatory Bowel Disease Diagnosis and Infliximab Response Prediction.肠道微生物群为炎症性肠病的诊断和英夫利昔单抗反应预测提供跨种族通用生物标志物。
mSystems. 2018 Jan 30;3(1). doi: 10.1128/mSystems.00188-17. eCollection 2018 Jan-Feb.
10
Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study.炎症性肠病患者停用抗TNF药物后的病情演变：一项多中心长期随访研究
Am J Gastroenterol. 2017 Jan;112(1):120-131. doi: 10.1038/ajg.2016.569. Epub 2016 Dec 13.
引用本文的文献
1
Predicting pediatric Crohn's disease based on six mRNA-constructed risk signature using comprehensive bioinformatic approaches.使用综合生物信息学方法基于六种mRNA构建的风险特征预测儿童克罗恩病。
Open Life Sci. 2023 Oct 5;18(1):20220731. doi: 10.1515/biol-2022-0731. eCollection 2023.
2
Association between HLA DNA Variants and Long-Term Response to Anti-TNF Drugs in a Spanish Pediatric Inflammatory Bowel Disease Cohort.HLA 基因变异与西班牙儿科炎症性肠病队列中抗 TNF 药物长期应答的相关性。
Int J Mol Sci. 2023 Jan 16;24(2):1797. doi: 10.3390/ijms24021797.
3
JNK pathway-associated phosphatase illustrates low expression and negative correlations with inflammation, disease activity, and T-helper 17 cells in inflammatory bowel disease children.JNK 通路相关磷酸酶在炎症性肠病儿童中表达水平较低，与炎症、疾病活动和辅助性 T 细胞 17 细胞呈负相关。
J Clin Lab Anal. 2022 Sep;36(9):e24488. doi: 10.1002/jcla.24488. Epub 2022 Jul 31.
本文引用的文献
1
Pharmacogenetic variants of infliximab response in young patients with inflammatory bowel disease.英夫利昔单抗治疗炎症性肠病青年患者反应的药物遗传学变异。
Clin Transl Sci. 2021 Nov;14(6):2184-2192. doi: 10.1111/cts.13075. Epub 2021 Jun 19.
2
Serum Adalimumab Levels After Induction Are Associated With Long-Term Remission in Children With Inflammatory Bowel Disease.诱导治疗后血清阿达木单抗水平与炎症性肠病患儿的长期缓解相关。
Front Pediatr. 2021 May 4;9:646671. doi: 10.3389/fped.2021.646671. eCollection 2021.
3
Development and Validation of an Interleukin-6 Nomogram to Predict Primary Non-response to Infliximab in Crohn's Disease Patients.用于预测克罗恩病患者对英夫利昔单抗原发性无反应的白细胞介素-6列线图的开发与验证
Front Pharmacol. 2021 Apr 14;12:654985. doi: 10.3389/fphar.2021.654985. eCollection 2021.
4
Evaluation of anti-TNF therapeutic response in patients with inflammatory bowel disease: Current and novel biomarkers.炎症性肠病患者抗 TNF 治疗反应的评估：当前和新型生物标志物。
EBioMedicine. 2021 Apr;66:103329. doi: 10.1016/j.ebiom.2021.103329. Epub 2021 Apr 13.
5
The Impact of Vitamin D on Response to Anti-tumor Necrosis Factor-α Therapy in Children With Inflammatory Bowel Disease.维生素 D 对炎症性肠病儿童抗肿瘤坏死因子-α治疗反应的影响。
J Pediatr Gastroenterol Nutr. 2021 May 1;72(5):e125-e131. doi: 10.1097/MPG.0000000000003064.
6
Interleukin 10 and interleukin 10 receptor in paediatric inflammatory bowel disease: from bench to bedside lesson.白细胞介素10及白细胞介素10受体与儿童炎症性肠病：从实验室到临床的经验教训
J Inflamm (Lond). 2021 Mar 10;18(1):13. doi: 10.1186/s12950-021-00279-3.
7
Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease.骨桥蛋白 M 是炎症性肠病的诊断、预后不良和治疗无应答的生物标志物。
Inflamm Bowel Dis. 2021 Oct 18;27(10):1564-1575. doi: 10.1093/ibd/izab032.
8
Microbial and metabolic features associated with outcome of infliximab therapy in pediatric Crohn's disease.与英夫利昔单抗治疗儿童克罗恩病结局相关的微生物和代谢特征。
Gut Microbes. 2021 Jan-Dec;13(1):1-18. doi: 10.1080/19490976.2020.1865708.
9
Whole Transcription Profile of Responders to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease.儿童炎症性肠病中抗TNF药物应答者的全转录谱
Pharmaceutics. 2021 Jan 8;13(1):77. doi: 10.3390/pharmaceutics13010077.
10
Using Personal Genomic Data within Primary Care: A Bioinformatics Approach to Pharmacogenomics.在初级保健中使用个人基因组数据：药物基因组学的生物信息学方法。
Genes (Basel). 2020 Nov 30;11(12):1443. doi: 10.3390/genes11121443.
Zotero 插件